Journal of Thrombosis and Thrombolysis

, Volume 28, Issue 4, pp 489–495 | Cite as

Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS)

  • Felicita Andreotti
  • Luciano Agati
  • Elena Conti
  • Eleonora Santucci
  • Teresa Rio
  • Federica Tarantino
  • Luigi Natale
  • Daniele Berardi
  • Antonella Mattatelli
  • Beatrice Musumeci
  • Lorenzo Bonomo
  • Massimo Volpe
  • Filippo Crea
  • Camillo Autore
Article
First Online:

Abstract

Erythropoietin (Epo) is a hematopoietic hormone produced mainly by the kidneys in response to hypoxia. Recent acquisitions in the fields of hematology, neurology, cardiology, and experimental medicine show cytoprotective, angiogenetic and antinflammatory effects of Epo. Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS, EudraCTno. 200500485386) is one of four ongoing randomized controlled trials, each testing the effects of Epo in ≥100 patients with STEMI. EPAMINONDAS is a multicenter, prospective, double-blind, placebo-controlled, dose-finding study assessing intravenous moderate doses of human recombinant Epo (epoietin-α, 100 or 200 IU/kg/die) versus placebo, given on the first 3 days, in 102 patients with first ST-segment elevation myocardial infarction. Initial dosing is within 12 h of primary percutaneous coronary revascularization. The primary endpoint is infarct size, quantified by CK-MB time–concentration curve, left ventricular wall motion score index, and pattern of contrast-enhanced magnetic resonance imaging. Secondary endpoints are ischemic recurrences, ventricular remodelling, and safety events, assessed in-hospital and at 12 months’ follow-up. The results of current phase II studies will help define the safety/efficacy profile of Epo for patients with STEMI.

Keywords

Human recombinant erythropoietin ST-segment elevation myocardial infarction Infarct size Primary PCI 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Van de Werf F, Bax J, Betriu A et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 29(23):2909–2945CrossRefPubMedGoogle Scholar
  2. 2.
    Fox KAA, Steg GP, Eagle KA et al (2007) Decline in rates of death and heart failure in acute coronary syndromes, 1999–2006. JAMA 297(17):1892–1900CrossRefPubMedGoogle Scholar
  3. 3.
    Biagini E, van Geuns RJ, Baks T et al (2006) Comparison between contrast echocardiography and magnetic resonance imaging to predict improvement of myocardial function after primary coronary intervention. Am J Cardiol 97(3):361–366CrossRefPubMedGoogle Scholar
  4. 4.
    Takemura G, Nakagawa M, Kanamori H, et al (2009) Benefits of reperfusion beyond infarct size limitation. Cardiovasc Res, Feb 18 (Epub ahead of print)Google Scholar
  5. 5.
    Andreotti F, Crea F, Conti E (2004) Heart-kidney interactions in ischemic syndromes. Circulation 109(5):e31–e32CrossRefPubMedGoogle Scholar
  6. 6.
    Conti E, Carrozza C, Capoluongo E et al (2004) Insulin-like growth factor-1 as a vascular protective factor. Circulation 110(15):2260–2265CrossRefPubMedGoogle Scholar
  7. 7.
    Conti E, Musumeci MB, Assenza GE et al (2008) Recombinant human insulin-like growth factor-1: a new cardiovascular disease treatment option? Cardiovasc Hematol Agents Med Chem 6(4):258–271CrossRefPubMedGoogle Scholar
  8. 8.
    Maiese K, Li F, Chong ZZ (2005) New avenues of exploration for erythropoietin. JAMA 293(1):90–95CrossRefPubMedGoogle Scholar
  9. 9.
    Bogoyevitch MA (2004) An update on the cardiac effects of erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 63(2):208–216CrossRefPubMedGoogle Scholar
  10. 10.
    Cai Z, Semenza GL (2004) Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 109(17):2050–2053CrossRefPubMedGoogle Scholar
  11. 11.
    van de Meer P, Lipsic E, Henning RH et al (2004) Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Failure 6(7):853–859Google Scholar
  12. 12.
    Heeschen C, Aicher A, Lehmann R et al (2003) Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102(4):1340–1346CrossRefPubMedGoogle Scholar
  13. 13.
    Messina E, De Angelis L, Frati G et al (2004) Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 95:852–854CrossRefGoogle Scholar
  14. 14.
    Fisher JW (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med 228(1):1–14Google Scholar
  15. 15.
    Marzo F, Lavorgna A, Coluzzi G et al (2008) Erythropoietin in heart and vessels: focus on transcription and signalling pathways. J Thromb Thrombolysis 26(3):183–187CrossRefPubMedGoogle Scholar
  16. 16.
    Riksen NP, Hausenloy DJ, Yellon DM (2008) Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci 29(5):258–267CrossRefPubMedGoogle Scholar
  17. 17.
    Fandrey J (2004) Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 286(6):R977–R988PubMedGoogle Scholar
  18. 18.
    Parsa CJ, Matsumoto A, Kim J et al (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112(7):999–1007PubMedGoogle Scholar
  19. 19.
    Calvillo L, Latini R, Kajstura J et al (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. PNAS 100(8):4802–4806CrossRefPubMedGoogle Scholar
  20. 20.
    Moon C, Krawczyk M, Ahn D et al (2003) Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. PNAS 100(20):11612–11617CrossRefPubMedGoogle Scholar
  21. 21.
    Hale SL, Sesti C, Kloner RA (2005) Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J Cardiovasc Pharmacol 46(2):211–215CrossRefPubMedGoogle Scholar
  22. 22.
    Moon C, Krawczyk M, Ahn D et al (2005) Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drug Ther 19(4):243–250CrossRefGoogle Scholar
  23. 23.
    Mancini DM, Katz SD, Lang CC et al (2003) Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107(2):294–299CrossRefPubMedGoogle Scholar
  24. 24.
    Silverberg DS, Wexler D, Sheps D et al (2001) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. JACC 37(7):1775–1780PubMedGoogle Scholar
  25. 25.
    Bohlius J, Langensiepen S, Schwarzer G et al (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97(7):489–498PubMedCrossRefGoogle Scholar
  26. 26.
    Iseki K, Nishime K, Uehara H et al (1996) Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients. Nephron 72(1):3036CrossRefGoogle Scholar
  27. 27.
    Wakeen M, Zimmerman SW (1998) Association between human recombinant EPO and peripheral vascular disease in diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 32(3):488–493CrossRefPubMedGoogle Scholar
  28. 28.
    Besarab A, Bolton WK, Browne JK et al (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339(9):584–590CrossRefPubMedGoogle Scholar
  29. 29.
    Ehrenreich H, Hasselblatt M, Dembowsky C et al (2002) Erythropoietin for acute stroke is both safe and beneficial. Mol Med 8(8):495–505PubMedGoogle Scholar
  30. 30.
    Corwin HL, Gettinger A, Fabian TC et al (2007) Efficacy and safety of epoietin alfa in critically ill patients. N Engl J Med 357:965–976CrossRefPubMedGoogle Scholar
  31. 31.
    Lipsic E, van der Meer P, Voors AA et al (2006) A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 20(2):135–141CrossRefPubMedGoogle Scholar
  32. 32.
    Belonje AM, Voors AA, van Gilst WH et al (2008) Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III). Am Heart J 155(5):817–822CrossRefPubMedGoogle Scholar
  33. 33.
    www.ClinicalTrial.gov Identifier: NCT 00378352
  34. 34.
    Ott I, Schulz S, Mehilli J, et al (2009) Prospective, randomized, double-blind, placebo-controlled trial of erythropoietin in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention (REVIVAL-3). Am Coll Cardiol Scientific Sessions 2009, Orlando, Fla (www.ClinicalTrial.gov Identifier: NCT00390832)
  35. 35.
    Liem A, van de Woestijne AP, Bruijns E et al (2009) Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int J Cardiol 131(2):285–287CrossRefPubMedGoogle Scholar
  36. 36.
    Andreotti F, Autore C, Conti E et al (2008) Safety and feasibility of erythropoietin administration in patients with acute ST-elevation myocardial infarction. Circulation 118:S876–S877Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Felicita Andreotti
    • 1
  • Luciano Agati
    • 3
  • Elena Conti
    • 4
  • Eleonora Santucci
    • 1
  • Teresa Rio
    • 1
  • Federica Tarantino
    • 1
  • Luigi Natale
    • 2
  • Daniele Berardi
    • 3
  • Antonella Mattatelli
    • 3
  • Beatrice Musumeci
    • 4
  • Lorenzo Bonomo
    • 2
  • Massimo Volpe
    • 4
    • 5
  • Filippo Crea
    • 1
  • Camillo Autore
    • 4
  1. 1.Institute of Cardiology, Department of Cardiovascular Medicine“A. Gemelli” University HospitalRomeItaly
  2. 2.Department of Radiology“A. Gemelli” University HospitalRomeItaly
  3. 3.Department of Cardiology, 1st Faculty“La Sapienza” UniversityRomeItaly
  4. 4.Department of Cardiology, 2nd Faculty“La Sapienza” UniversityRomeItaly
  5. 5.IRCCS, NeuromedPozzilli (Is)Italy

Personalised recommendations